Navigation Links
Neurobiological Technologies Reports Second Quarter Financial Results
Date:2/11/2008

- Conference Call at 10:30 a.m. ET -

EMERYVILLE, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for its fiscal second quarter and the six-months ended Dec. 31, 2007.

Revenues for the second quarter of 2007 were $3.7 million compared to $4.0 million in the same quarter last year. Research and development expenses were $7.4 million in the three months ended Dec. 31, 2007 versus $5.7 million in the same period last year.

General and administrative expenses were $1.9 million for the three months ended Dec. 31, 2007 versus $1.6 million in the same period last year.

Net loss for the second quarter ended Dec. 31, 2007 was $6.9 million, or $0.36 per share, compared with a net loss of $3.1 million, or $0.74 per share, for the second quarter of 2006.

Revenues for the first six months of fiscal 2007 were $7.6 million versus $8.8 million in the same period of 2006. Research and development expenses were $12.9 million in the six months ended Dec. 31, 2007 versus $11.5 million in the same period of 2006. General and administrative expenses were $3.6 million for the six months ended Dec. 31 compared to expenses of $3.1 million for the same period in 2006. Net loss for the six months ended Dec. 31, 2007 was $7.8 million, or $0.65 per share, compared to net loss of $5.5 million, or $1.31 per share, for the six-months ended Dec. 31, 2006.

Cash, cash equivalents and total investments were $52.8 million at December 31, 2007.

Paul Freiman, NTII president and chief executive officer stated, "During the quarter, we completed an offering underwritten by Merriman Curhan & Ford that raised $55 million of net proceeds. This will support our Phase 3 clinical trials for Viprinex(TM). We are pleased that the investors in this offering included existing shareholders, significant new institutional investors and members of our Board of Directors. We continue to invest in our key asset, Viprinex, for acute ischemic stroke currently in two Phase III clinical trials. We believe Viprinex has the potential to double the treatment window over the current approved drug, while at the same time reducing the major side effects of fibrinolytics, namely, symptomatic intracranial hemorrhage."

Freiman continued: "I am also very pleased Dr. Warren Wasiewski, who joined NTII in February 2007 as Vice President, Clinical Programs was promoted to Chief Medical Officer of NTII with primary responsibility for running the clinical trial program for Viprinex. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTII, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate."

About Viprinex Phase 3 Trial Program

Viprinex is an investigational agent with multiple novel mechanisms of action that appear to have the potential to expand the treatment window for treating acute ischemic stroke with a lower risk of intracranial bleeding. The only approved agent to treat stroke is required to be given within the first three hours of stroke symptoms primarily due to increased bleeding risk beyond that window. This time limit has been a barrier to receiving care and improving outcomes and quality of life for stroke patients. Previous large Phase III trials have demonstrated that Viprinex may be effective and appears to be well tolerated for acute ischemic stroke.

Conference Call Information

NTI will webcast its quarterly financial results and host a conference call on Monday, February 11, 2007 at 10:30 a.m. (ET), 7:30 a.m. (PT). Dial-in number (877) 857-6147 (U.S. and Canada) and 719-325-4822 (International). The live webcast can be accessed by going to http://investor.shareholder.com/ntii/events.cfm. A playback of the conference call will be available from 1:30 p.m. (ET) on February 11, 2007 through 11:59 p.m. (ET) on February 15, 2007. Replay number: (888) 203-1112 (U.S. and Canada) / (719) 457-0820 (international). Replay access code: 3898964.

About Neurobiological Technologies, Inc.

NTI is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate is Viprinex (ancrod), a novel multi-targeted agent currently undergoing pivotal Phase 3 clinical testing for the potential treatment of acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the timing for completion of clinical trials, obtaining approval for Viprinex, our levels of future expenditures and capital resources and our need to raise additional capital to fund our operations, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended Six months ended

December 31, December 31,

2007 2006 2007 2006

REVENUES

Technology sale and

collaboration

services $1,559,937 $2,365,243 $3,479,294 $5,556,915

Royalty 2,103,186 1,655,052 4,083,629 3,244,115

Total revenues 3,663,123 4,020,295 7,562,923 8,801,030

EXPENSES

Research and

development 7,416,295 5,680,680 12,876,721 11,539,139

General and

administrative 1,912,276 1,565,672 3,571,071 3,059,321

Total expenses 9,328,571 7,246,352 16,447,792 14,598,460

Operating loss (5,665,448) (3,226,057) (8,884,869) (5,797,430)

Investment income 451,887 115,728 479,746 269,365

Interest expense,

including non-cash

amortization of

discount on notes

of $1,748,268 and

$2,336,097. (1,846,385) - (2,478,597) -

Non-cash gain on

change in fair value

of warrants 176,849 - 3,079,130 -

NET LOSS $(6,883,097) $(3,110,329) $(7,804,590) $(5,528,065)

BASIC AND DILUTED

NET LOSS PER SHARE $(0.36) $(0.74) $(0.65) $(1.31)

Shares used in basic

and diluted net loss

per share calculation 19,312,845 4,222,654 12,042,296 4,222,643

SELECTED BALANCE SHEET DATA

December 31, 2007 June 30, 2007

(unaudited) (1)

Cash and cash

equivalents &

investments $52,791,000 $8,904,000

Working capital 43,691,000 (3,974,000)

Total assets 54,005,000 10,921,000

Accumulated deficit (117,074,000) (109,269,000)

Stockholders' equity

(deficit) 27,817,000 (22,093,000)

(1) Derived from audited financial statements


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurobiological Technologies Reports Going Concern Qualification
2. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
3. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
6. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
7. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
8. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
9. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. Advanced technologies aim to transform the coaching of top athletes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology: